Complement C1 inhibitor protein - Shire plc

Drug Profile

Complement C1 inhibitor protein - Shire plc

Alternative Names: C1 Esterase Inhibitor (human); C1 INH-nf; C1-INH; Cetor; Cinryze; SHP-616

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Sanquin Blood Supply Foundation
  • Developer Sanquin Blood Supply Foundation; Shire; Shire ViroPharma; ViroPharma
  • Class Complement C1 inactivator proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase III Transplant rejection
  • Phase I Neuromyelitis optica
  • Clinical Phase Unknown Autoimmune haemolytic anaemia
  • Preclinical Delayed graft function
  • No development reported Myocardial infarction
  • Discontinued Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 16 Mar 2017 Registered for Hereditary angioedema (In children) in European Union (IV)
  • 16 Mar 2017 Registered for Hereditary angioedema (In children, Prevention) in European Union (IV)
  • 16 Mar 2017 Shire announces planned launch for use in paediatric patients later in 2017 throughout the member states of the EU and the EEA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top